axicabtagene ciloleucel,lisocabtagene maraleucel
gilead,bms,daiichi sankyo
['transform,(-transformi),(-transforme),(-transforma),(-transforms),(-transform1),(-transform 1),(-transform-1),(-transform2),(-transform 2),(-transform-2)', 'zuma 7', 'dlbcl']
polar-ice in r/r dlbcl. crr 56%: higher in relapsed vs primary refractory. 61% bridged to asct (vs around 40% for zuma 7-transform, most pts would have been eligible for those trials). 10% mobilization failures. really promising, sp in latam with limited access to cart #ash22 
hematologa en Fleming, lymphoma fan, mama de Luchi, un poco yogi y mucha acuarela!